Ironwood Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Ironwood Pharmaceuticals has a total shareholder equity of $-311.3M and total debt of $598.8M, which brings its debt-to-equity ratio to -192.3%. Its total assets and total liabilities are $389.5M and $700.9M respectively. Ironwood Pharmaceuticals's EBIT is $95.4M making its interest coverage ratio 3.4. It has cash and short-term investments of $88.2M.
Key information
-192.3%
Debt to equity ratio
US$598.82m
Debt
| Interest coverage ratio | 3.4x |
| Cash | US$88.21m |
| Equity | -US$311.33m |
| Total liabilities | US$700.85m |
| Total assets | US$389.52m |
Recent financial health updates
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Recent updates
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 21Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
Oct 24Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Aug 16Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
Jun 27Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Jun 20Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Financial Position Analysis
Short Term Liabilities: IRWD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IRWD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IRWD has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IRWD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable IRWD has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: IRWD is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.5% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 05:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ironwood Pharmaceuticals, Inc. is covered by 37 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |